A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study is the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.
Checked against the public recordLast updated Feb 8, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Pfizer
- Interventions being studied
- Drug: PF-02341066; Drug: Rifampin; Drug: Itraconazole
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Advanced malignancies (except leukemias), histologically proven at diagnosis; Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS * Solid tumors must have measurable disease (Recommended Phase 2 Dose Cohort patients with non-measurable disease may enter on a case-by-case basis); not required for DDI sub-studies. * Adequate blood cell counts, kidney function, liver function and Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 (for the Recommended Phase 2 Cohort, a ECOG score of 2 may be allowed on a case-by-case basis) Exclusion Criteria: * Major surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of starting study treatment, depending on the patient cohort * Prior stem cell transplant except of patients with neuroblastoma, lymphoma or myeloma * Active or unstable cardiac disease or heart attack within 3 months of starting study treatment
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of California, Irvine Medical CenterOrange, California
- University of Colorado Hospital/ Anschutz Cancer PavilionAurora, Colorado
- University of Colorado HospitalAurora, Colorado
- University of ColoradoAurora, Colorado
- University of ChicagoChicago, Illinois
- Massachusetts General HospitalBoston, Massachusetts
- Ophthalmic Consultants of Boston Inc.Boston, Massachusetts
- Beth Israel Deaconess Medical CenterBoston, Massachusetts
- Dana Farber Cancer CenterBoston, Massachusetts
- Joslin Beetham Eye InstituteBoston, Massachusetts
- Karmanos Cancer InstituteDetroit, Michigan
- Kresge Eye InstituteDetroit, Michigan
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 8, 2023. Always confirm current availability with the study team.